Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Lexaria Bioscience Corp. (LEXX : NSDQ)

• Company Description    Lexaria Bioscience Corp. provides drug delivery platforms. Its patented DehydraTECH(TM) drug delivery technology changes the way Active Pharmaceutical Ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. Lexaria Bioscience Corp. is based in Kelowna, Canada. Number of Employees: 7

• Price / Volume Information    Yesterday's Closing Price: $0.66 Daily Weekly Monthly 20 Day Moving Average: 168,970 shares Shares Outstanding: 24.89 (millions) Market Capitalization: $16.43 (millions) Beta: 0.56 52 Week High: $1.90 52 Week Low: $0.46 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -17.50% -17.57% 12 Week -41.07% -41.66% Year To Date 6.97% 6.41%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 100 - 740 MCCURDY ROAD - KELOWNA,A1 V1X 2P7 CAN ph: 250-765-6424 fax: - ir@lexariabioscience.com http://www.lexariabioscience.com

• General Corporate Information    Officers Richard Christopher - Chief Executive Officer Christopher Bunka - Chairman John Docherty - President Michael Shankman - Chief Financial Officer Ted McKechnie - Director Peer Information Lexaria Bioscience Corp. (CORR.) Lexaria Bioscience Corp. (RSPI) Lexaria Bioscience Corp. (CGXP) Lexaria Bioscience Corp. (BGEN) Lexaria Bioscience Corp. (GTBP) Lexaria Bioscience Corp. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 52886N406 SIC: 2834 Fiscal Year Fiscal Year End: August Last Reported Quarter: 11/01/25 Next Expected EPS Date: 04/13/26 Share - Related Items Shares Outstanding: 24.89 Most Recent Split Date: 1.00 (0.03:1) Beta: 0.56 Market Capitalization: $16.43 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.09 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.36 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 04/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.63 Price/Cash Flow: - Price / Sales: 23.27 EPS Growth vs. Year Ago Period: 56.25% vs. Previous Quarter: 46.15% Sales Growth vs. Year Ago Period: 107.14% vs. Previous Quarter: 0.00% ROE 11/30/25 - -226.58 08/31/25 - -198.99 05/31/25 - -157.22 ROA 11/30/25 - -168.35 08/31/25 - -162.00 05/31/25 - -133.69 Current Ratio 11/30/25 - 3.68 08/31/25 - 2.32 05/31/25 - 3.90 Quick Ratio 11/30/25 - 3.68 08/31/25 - 2.32 05/31/25 - 3.90 Operating Margin 11/30/25 - - 08/31/25 - -1,685.84 05/31/25 - -1,849.19 Net Margin 11/30/25 - - 08/31/25 - -1,685.84 05/31/25 - -1,849.19 Pre-Tax Margin 11/30/25 - -2,068.97 08/31/25 - -1,687.11 05/31/25 - -1,850.97 Book Value 11/30/25 - 0.18 08/31/25 - 0.13 05/31/25 - 0.29 Inventory Turnover 11/30/25 - - 08/31/25 - - 05/31/25 - - Debt-to-Equity 11/30/25 - 0.00 08/31/25 - 0.00 05/31/25 - 0.00 Debt-to-Capital 11/30/25 - 0.00 08/31/25 - 0.00 05/31/25 - 0.00

Powered by Zacks Investment Research ©